Pricing updated 2019-04-24. Prices are subject to change without notice.
Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy.1 BMS-265246 is a cell-permeable inhibitor of Cdk1/cyclin B and Cdk2/cyclin E (IC50s = 6 and 9 nM, respectively).2 It less potently inhibits Cdk4/cyclin D (IC50 = 0.23 μM).2 BMS-265246 blocks the cycling of HCT116 cells (EC50 = 0.29-0.49 µM), resulting in cell cycle arrest in G2 phase.3
Warning - this product is not for human or veterinary use.
View the Cayman Structure Database for chemical structure definitions for many Cayman products
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data pack, and GC-MS data.
Bettayeb, K., Baunbaek, D., Delehouze, C., et al. CDK inhibitors roscovitine and CR8 trigger Mcl-
Misra, R.N., Xiao, H., Rawlins, D.B., et al. 1H-
Sutherland, J.J., Low, J., Blosser, W., et al. A robust high-